News and Articles

• The European Commission approved PYRUKYND (mitapivat) for adults with thalassemia, making it the only EU-approved treatment covering all forms of the disease.
• Mitapivat is now approved in the US, Saudi Arabia, UAE, and EU, expanding commercial manufacturing and procurement requirements for pyruvate-chain biochemicals including sodium pyruvate.
• Avanzanite Bioscience BV will commercialize PYRUKYND across the EEA, UK, and Switzerland, establishing a European commercial infrastructure for this pyruvate kinase activator class.
• Combined Phase 3 data from ENERGIZE and ENERGIZE-T enrolled 452 thalassemia patients, with 18,000 to 23,000 thalassemia patients in the US and EU5 representing the addressable patient population.
• Agios' pipeline also includes tebapivat in Phase 2b for myelodysplastic syndromes, extending the sodium pyruvate demand signal across multiple drug programs in the PK activator class.

The European Commission granted marketing authorization on May 22, 2026, for PYRUKYND (mitapivat), an oral pyruvate kinase activator developed by Agios Pharmaceuticals, for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. The decision makes PYRUKYND the only medicine approved across all European Union member states for this broad patient population, and brings the drug's geographic reach to four major markets: the United States, Saudi Arabia, the United Arab Emirates, and the EU.

The EU authorization carries commercial significance for the broader pyruvate pharmaceutical supply chain. Mitapivat works by activating pyruvate kinase, an enzyme central to glycolysis and red blood cell energy metabolism. Manufacturing this class of drug and supporting clinical programs at scale requires sodium pyruvate and other pyruvate-chain compounds in cell culture media, preclinical research substrates, and quality control testing. Each new geographic approval for mitapivat expands the number of commercial production sites and clinical infrastructure requiring pharmaceutical-grade pyruvate biochemicals.

Request the Latest Sodium Pyruvate Prices Data - Access Price Insights Now

Avanzanite Bioscience BV, a specialty pharmaceutical company headquartered in Amsterdam, will distribute and commercialize PYRUKYND across the European Economic Area, the United Kingdom, and Switzerland under the agreement with Agios entered in 2025. The establishment of a dedicated European commercial operation for this product class is likely to increase demand for compliant sodium pyruvate supply from European pharmaceutical manufacturers and contract development organizations supporting the program.

The approval is supported by Phase 3 data from the ENERGIZE and ENERGIZE-T trials, which enrolled a combined 452 adults with alpha- or beta-thalassemia. An estimated 18,000 to 23,000 patients with thalassemia live in the US and the five largest European countries alone. As treatment uptake builds across approved geographies, demand for pyruvate kinase activator manufacturing inputs is expected to grow in parallel.

Beyond mitapivat, the broader class of pyruvate kinase activators is advancing in development. Agios also has tebapivat in a Phase 2b trial for myelodysplastic syndromes, with data updates shared as recently as May 29, 2026. An expanding pipeline in this compound class creates a growing and durable procurement channel for sodium pyruvate in pharmaceutical development and manufacturing settings.

Procurement teams sourcing sodium pyruvate for cell culture media, pharmaceutical ingredient manufacturing, or research reagent supply should note the expanding commercial footprint of PK activator drugs as a structural demand driver. Supply of pharmaceutical-grade sodium pyruvate remains concentrated in China, and pre-qualified supplier contracts with defined purity specifications are advisable for organizations supporting biopharmaceutical programs in this drug class.